copper toxicity ghk cu GHK-Cu – Y&P Labs GHK-Cu Research Compound | Axiom

Description

Retatrutide Research# The pivotal Phase 2 trial (338 participants, NEJM 2023) showed 24.2% weight loss at 48 weeks

Minimally invasive techniques are used when they are the right choice, not as a default

Peptide Therapy Adults Over 60: Who Is and Is Not a Candidate Strong Candidates Adults 60+ with documented low IGF-1 on serum testing Individuals with sarcopenia confirmed by DEXA or functional testing Active seniors experiencing delayed recovery, poor sleep, and reduced energy not explained by other pathology Adults managing visceral obesity with inadequate response to diet and exercise Individuals already on andropause or menopause hormone therapy who want adjunctive metabolic support Poor Candidates or Contraindicated Any history of active cancer (especially hormone-sensitive: prostate, breast, colon) Uncontrolled diabetes (HbA1c above 8.5%) Severe cardiac or renal impairment Active intracranial pathology (GH secretagogues stimulate pituitary